US biotech firms Arrowhead, Arvinas and Intapp report quarterly results

Arrowhead Pharmaceuticals posted a quarterly loss of $1.36 per share, missing the consensus estimate of $1.23, while revenue surged to $75.25 million, well above the $44.17 million forecast. The company reported a net loss of $194.3 million, held about $1.6 billion in cash, and announced approvals in Australia and the European Union, a priority‑review voucher purchase for $215 million, and upcoming data releases for several pipeline candidates.

Arvinas reported earnings of $2.58 per share, beating the consensus estimate of a $0.37 loss, and generated $249.70 million in revenue, far exceeding the $60.71 million expected. Revenue grew more than ten‑fold year‑over‑year. BTIG Research reiterated a buy rating on Arvinas with an $18 target price, while other analysts offered mixed ratings ranging from sell to hold.

Intapp, Inc. held its fiscal fourth‑quarter 2026 earnings call, presenting its financial results and outlook for 2027. Management discussed forward‑looking statements, non‑GAAP metrics, and strategic initiatives, but specific financial figures were not disclosed in the transcript.